■ 学会名
17th Scientific Meeting of the Asian Association for the Study of Diabetes (AASD 2025)

■ 発表日
2025/03/28-30

■ 筆頭演者
Takeshi Horii
Faculty of Pharmacy, Musashino University, Tokyo, Japan

■ 共同演者
Yoichi Oikawa¹, Akira Shimada¹, Kiyoshi Mihara²
1) Department of Endocrinology and Diabetes, Saitama Medical University, Saitama, Japan
2) Faculty of Pharmacy, Musashino University, Tokyo, Japan

■ 発表形態
Poster

■ 要旨
Objective:
This study aims to elucidate the necessary treatment strategies to prevent the progression of LEAD in patients with T2D using large-scale claim data.
Methods:
This study is a retrospective cross-sectional study. The study’s outcome is on the progression of LEAD, which is defined as the administration of endovascular therapy in individuals diagnosed with T2D and LEAD.
Results:
The progression of LEAD was observed in 920/257,951 (0.36%) patients with T2D. The OR for the progression of LEAD decreased significantly in SGLT2I (OR:0.52), biguanides (OR:0.76), and fibrates (OR:0.79). On the other hand, older patients with a 10-year age increments (OR:1.24), BMI of <18.5 kg/m2 (OR:1.75), eGFR <30mL/min/1.73m2 (OR:3.18), smoking status (OR:2.08), insulin (OR:1.39), and sulfonylureas (OR:1.22) were associated with a higher odds ratio. Conclusions: This study found that several agents may be effective in reducing the progression of LEAD. Furthermore, many other management targets for atherosclerosis may be effective in mitigating the progression of LEAD.